![]() |
Name |
2-Methyl-3,5-dihydroxy-6-methoxy-1,4-benzoquinone
|
Molecular Formula | C8H8O5 | |
IUPAC Name* |
2,6-dihydroxy-3-methoxy-5-methylcyclohexa-2,5-diene-1,4-dione
|
|
SMILES |
CC1=C(C(=O)C(=C(C1=O)OC)O)O
|
|
InChI |
InChI=1S/C8H8O5/c1-3-4(9)6(11)7(12)8(13-2)5(3)10/h9,12H,1-2H3
|
|
InChIKey |
OXXPMFLZLUGGPV-UHFFFAOYSA-N
|
|
Synonyms |
Fumiquinone B; 2-Methyl-3,5-dihydroxy-6-methoxy-1,4-benzoquinone; 2,6-dihydroxy-5-methoxy-3-methylcyclohexa-2,5-diene-1,4-dione
|
|
CAS | NA | |
PubChem CID | 136773313 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 184.15 | ALogp: | 0.3 |
HBD: | 2 | HBA: | 5 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 83.8 | Aromatic Rings: | 1 |
Heavy Atoms: | 13 | QED Weighted: | 0.588 |
Caco-2 Permeability: | -4.788 | MDCK Permeability: | 0.00016336 |
Pgp-inhibitor: | 0.02 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.096 |
Blood-Brain-Barrier Penetration (BBB): | 0.37 | Plasma Protein Binding (PPB): | 82.55% |
Volume Distribution (VD): | 0.431 | Fu: | 10.00% |
CYP1A2-inhibitor: | 0.248 | CYP1A2-substrate: | 0.751 |
CYP2C19-inhibitor: | 0.126 | CYP2C19-substrate: | 0.081 |
CYP2C9-inhibitor: | 0.133 | CYP2C9-substrate: | 0.392 |
CYP2D6-inhibitor: | 0.279 | CYP2D6-substrate: | 0.107 |
CYP3A4-inhibitor: | 0.01 | CYP3A4-substrate: | 0.109 |
Clearance (CL): | 1.448 | Half-life (T1/2): | 0.26 |
hERG Blockers: | 0.007 | Human Hepatotoxicity (H-HT): | 0.681 |
Drug-inuced Liver Injury (DILI): | 0.737 | AMES Toxicity: | 0.074 |
Rat Oral Acute Toxicity: | 0.727 | Maximum Recommended Daily Dose: | 0.007 |
Skin Sensitization: | 0.768 | Carcinogencity: | 0.011 |
Eye Corrosion: | 0.063 | Eye Irritation: | 0.957 |
Respiratory Toxicity: | 0.951 |